Ulipristal Acetate
Brand names: Esmya (fibroids), EllaOne (emergency contraception)
Ulipristal acetate is a selective progesterone-receptor modulator used as emergency contraception, effective when taken up to 120 hours (5 days) after unprotected sex. It may be more effective than levonorgestrel, particularly later in the cycle.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
US labelling (FDA)
Reference — US labelling, may differ from UKTake one tablet orally as soon as possible, within 120 hours (5 days) after unprotected intercourse or a known or suspected contraceptive failure. Take with or without food. Take at any time during the menstrual cycle. ( 2.1 ) After ella use, initiate or resume hormonal contraception no sooner than 5 days after the intake of ella and use a reliable barrier method until the next menstrual period. ( 2.2 ) If vomiting occurs within 3 hours of taking ella , consider repeating the dose. ( 2.3 ) 2.1 Recommended Dosage and Administration Take one tablet of ella orally as soon as possible within 120 hours (5 days) after unprotected intercourse or a known or suspected contraceptive failure. Take …
Source: US FDA prescribing information (openFDA / DailyMed), label dated 2026-01-07. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.
Clinical monograph
How it works
It modulates the progesterone receptor to delay or inhibit ovulation, including when taken close to the time of ovulation; it is not an abortifacient.
Prescribing in practice
- Starting or restarting hormonal (progestogen) contraception immediately afterwards reduces its effectiveness, so wait the recommended interval before doing so.
- Avoid in severe asthma that is inadequately controlled by oral corticosteroids.
- Enzyme-inducing drugs reduce its effectiveness, in which case a copper intrauterine device is preferred.
Monitoring
No routine monitoring is required; advise a pregnancy test if the next period is late or unusually light, and arrange ongoing contraception after the recommended interval.
Counselling the patient
- Take it as soon as possible after unprotected sex, up to five days afterwards.
- Do not start or restart hormonal contraception straight away; use condoms or abstain until your prescriber advises it is time, then continue reliable contraception.
- If you vomit within a few hours of the dose, seek advice as you may need to repeat it.
Evidence & guidelines
Recommended emergency contraceptive option (FSRH; NICE CKS).
Reference: MHRA Drug Safety Update (2020) — Esmya liver injury; PEARL trials I-IV (Donnez et al. NEJM 2012); NICE TA519; SPC Esmya; SPC EllaOne; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- EDACS — Emergency Department Assessment of Chest Pain · Chest Pain
- San Francisco Syncope Rule · Syncope
- ROSE Rule for Syncope · Syncope
- Ottawa Heart Failure Risk Scale · Heart Failure
- Aortic Dissection Detection Risk Score (ADD-RS) · Aortic Disease
- Emergency Heart Failure Mortality Risk Grade (EHMRG) · Heart Failure